182 related articles for article (PubMed ID: 26245169)
1. Influence of allelic Variations of hypoxia-related and DNA repair genes on patient outcome and toxicity in head and neck cancer treated with radiotherapy plus cetuximab.
Muñoz C; Caballero M; Hakim S; Verger E; Grau JJ
Eur Arch Otorhinolaryngol; 2016 Aug; 273(8):2193-9. PubMed ID: 26245169
[TBL] [Abstract][Full Text] [Related]
2. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
3. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
[TBL] [Abstract][Full Text] [Related]
4. DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck.
Farnebo L; Stjernström A; Fredrikson M; Ansell A; Garvin S; Thunell LK
DNA Repair (Amst); 2015 Jul; 31():64-72. PubMed ID: 26001739
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Mizumachi T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H; Homma A
Int J Clin Oncol; 2019 May; 24(5):468-475. PubMed ID: 30656463
[TBL] [Abstract][Full Text] [Related]
7. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.
Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T
Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692
[TBL] [Abstract][Full Text] [Related]
8. Association between genetic polymorphisms in DNA mismatch repair-related genes with risk and prognosis of head and neck squamous cell carcinoma.
Nogueira GA; Lourenço GJ; Oliveira CB; Marson FA; Lopes-Aguiar L; Costa EF; Lima TR; Liutti VT; Leal F; Santos VC; Rinck-Junior JA; Lima CS
Int J Cancer; 2015 Aug; 137(4):810-8. PubMed ID: 25598504
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of XRCC1 Gene Polymorphism as a Biomarker in Head and Neck Cancer Patients Undergoing Chemoradiation Therapy.
Nanda SS; Gandhi AK; Rastogi M; Khurana R; Hadi R; Sahni K; Mishra SP; Srivastava AK; Bhatt MLB; Parmar D
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):593-601. PubMed ID: 29893275
[TBL] [Abstract][Full Text] [Related]
10. Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
Sakashita T; Homma A; Hatakeyama H; Furusawa J; Kano S; Mizumachi T; Iizuka S; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
Acta Otolaryngol; 2015 Aug; 135(8):853-8. PubMed ID: 25814008
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
13. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial.
Bonner JA; Giralt J; Harari PM; Baselga J; Spencer S; Bell D; Raben D; Liu J; Schulten J; Ang KK; Rosenthal DI
Eur J Cancer; 2016 Sep; 64():1-11. PubMed ID: 27323346
[TBL] [Abstract][Full Text] [Related]
14. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer.
Winter SC; Shah KA; Han C; Campo L; Turley H; Leek R; Corbridge RJ; Cox GJ; Harris AL
Cancer; 2006 Aug; 107(4):757-66. PubMed ID: 16826581
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer.
Bibault JE; Morelle M; Perrier L; Pommier P; Boisselier P; Coche-Dequéant B; Gallocher O; Alfonsi M; Bardet É; Rives M; Calugaru V; Chajon E; Noël G; Mecellem H; Pérol D; Dussart S; Giraud P
Cancer Radiother; 2016 Jul; 20(5):357-61. PubMed ID: 27345843
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma.
Wang WM; Zhao ZL; Ma SR; Yu GT; Liu B; Zhang L; Zhang WF; Kulkarni AB; Sun ZJ; Zhao YF
PLoS One; 2015; 10(2):e0119723. PubMed ID: 25723392
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients.
Beasley NJ; Leek R; Alam M; Turley H; Cox GJ; Gatter K; Millard P; Fuggle S; Harris AL
Cancer Res; 2002 May; 62(9):2493-7. PubMed ID: 11980639
[TBL] [Abstract][Full Text] [Related]
18. Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy.
Rambeau A; Gervais R; De Raucourt D; Babin E; Dugué AE; Florescu C; Blanchard D; Gery B
Eur Arch Otorhinolaryngol; 2017 Jul; 274(7):2883-2889. PubMed ID: 28382396
[TBL] [Abstract][Full Text] [Related]
19. The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients.
Hirasawa K; Okamoto I; Motohashi R; Sato H; Takase S; Agata A; Takeda A; Tsukahara K
Auris Nasus Larynx; 2017 Dec; 44(6):724-728. PubMed ID: 28237712
[TBL] [Abstract][Full Text] [Related]
20. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
